BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
Accessnewswire·2025-11-04 16:05
公司动态 - 公司全资德国子公司Vektor Pharma TF GmbH收到欧洲专利局的"意向授权"通知 [1] - 相关欧洲专利申请号为23 729 446 7 [1] - 专利涵盖用于治疗多发性硬化症及相关神经退行性疾病的氯脲霉素舌下口服分散薄膜制剂 [1]